How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?

The paper supporting the 'early morning' approach has been retracted, and arguments against this are being actively pursued for full publication. Recently, data were presented at AACR as well. The half-life of these molecules is quite long (in the range of weeks), which raises a question against the...